This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Almac Discovery Limited. Active years: 2021-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021-2025
Title: Mary Melissa McFarland: Innovator in Pharmaceutical Compounds
Introduction
Mary Melissa McFarland is a notable inventor based in Craigavon, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit specific proteases. With a total of 2 patents to her name, her work is recognized for its potential therapeutic applications.
Latest Patents
Mary Melissa McFarland's latest patents focus on pharmaceutical compounds that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The inventions relate to compounds of Formula (I) and include pharmaceutical compositions comprising these compounds. These innovations are aimed at providing methods for using these compounds in therapy, showcasing her commitment to advancing medical science.
Career Highlights
Mary is currently associated with Almac Discovery Limited, where she continues to push the boundaries of pharmaceutical research. Her work has been instrumental in developing new therapeutic strategies that could benefit patients worldwide.
Collaborations
Throughout her career, Mary has collaborated with esteemed colleagues such as Peter Hewitt and James Samuel Shane Rountree. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Mary Melissa McFarland stands out as a dedicated inventor in the pharmaceutical industry. Her contributions to the development of innovative compounds demonstrate her expertise and commitment to improving healthcare solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile